$1.78 Billion is the total value of Boxer Capital, LLC's 73 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 52.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | AMYLYX PHARMACEUTICALS INC | $58,665,000 | +38.5% | 2,084,000 | -5.3% | 3.30% | +22.9% | |
| RLAY | Sell | RELAY THERAPEUTICS INC | $48,523,000 | +8.5% | 2,169,132 | -18.7% | 2.73% | -3.6% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $37,649,000 | -24.5% | 3,163,795 | -9.6% | 2.12% | -33.0% |
| KNTE | Sell | KINNATE BIOPHARMA INC | $18,195,000 | -21.9% | 1,522,559 | -17.6% | 1.02% | -30.7% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $18,120,000 | -29.3% | 275,000 | -45.8% | 1.02% | -37.2% |
| FATE | Sell | FATE THERAPEUTICS INC | $7,844,000 | -36.7% | 350,000 | -30.0% | 0.44% | -43.8% |
| MIST | Sell | MILESTONE PHARMACEUTICALS IN | $6,423,000 | -53.4% | 698,861 | -68.8% | 0.36% | -58.6% |
| CDAK | Sell | CODIAK BIOSCIENCES INC | $382,000 | -84.4% | 488,157 | -42.6% | 0.02% | -86.5% |
| ELEV | Exit | Elevation Oncology Inc | $0 | – | -872,780 | -100.0% | -0.08% | – |
| ALGS | Exit | Aligos Therapeutics Inc | $0 | – | -1,526,048 | -100.0% | -0.12% | – |
| EPIX | Exit | Essa Pharma Inc | $0 | – | -724,500 | -100.0% | -0.14% | – |
| SLDB | Exit | Solid Biosciences Inc | $0 | – | -5,336,031 | -100.0% | -0.21% | – |
| GHRS | Exit | GH Research PLCordinary shares | $0 | – | -1,013,399 | -100.0% | -0.64% | – |
| NUVB | Exit | Nuvation Bio Inc | $0 | – | -4,341,009 | -100.0% | -0.89% | – |
| BMEA | Exit | Biomea Fusion Inc | $0 | – | -1,188,405 | -100.0% | -0.90% | – |
| XBI | Exit | SPDR SER TRs&p biotech | $0 | – | -500,000 | -100.0% | -2.35% | – |
| TPTX | Exit | Turning Point Therapeutics I | $0 | – | -570,745 | -100.0% | -2.72% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.